5/11/2020 8:45:19 PM
AtriCure Prices Public Offering Of 3.98 Mln Shares At $44.00/shr
5/11/2020 7:18:20 AM
AtriCure Expects To Sell About $100 Mln Of Common Shares
5/8/2020 8:50:19 AM
AtriCure Announces Results From CONVERGE IDE Clinical Trial
4/9/2020 8:11:04 AM
AtriCure Exoects Q1 Preliminary Revenue To Be $53.2 Mln; Withdraws 2020 Outlook
8/13/2019 2:47:55 PM
AtriCure Completes Acquisition Of SentreHEART
4/23/2019 8:04:59 AM
AtriCure Announces First Patient Enrollment In The DEEP IDE Trial Restart
2/12/2019 8:02:17 AM
AtriCure Announces Launch Of CryoICE CryoSPHERE Probe
2/5/2019 8:05:07 AM
AtriCure Announces First Patient Enrolled In The ICE-AFIB Clinical Trial
10/3/2018 4:02:30 PM
AtriCure Expects Q3 Revenue Of Approx. $49.9 Mln
10/3/2018 4:01:56 PM
AtriCure Announces Proposed Public Offering Of Common Stock
8/28/2018 8:04:49 AM
AtriCure Completes Patient Enrollment In The CONVERGE IDE Clinical Trial
7/24/2018 4:32:58 PM
ViewRay Appoints Scott Drake As President, CEO And Director
6/5/2018 6:03:04 AM
AtriCure Partners With Baheal In China To Distribute Surgical Ablation Devices
1/8/2018 8:20:59 AM
AtriCure Expects Q4 Revenue To Be About $46.1 Mln,FY17 Revenue $174.7 Mln
9/12/2017 8:12:33 AM
AtriCure Announces U.S. Launch Of The AtriClip PRO•V Device
7/18/2017 4:15:47 PM
AtriCure Hires Salvatore Privitera As Its Chief Technology Officer